T cell engineering category | Trial Phase | Enrolled patients backgrounds | Trial information | Reference | ||||||
---|---|---|---|---|---|---|---|---|---|---|
I | II | III | Number. | Location | intervention | Antigen | comments | Identifier | ||
TCR-T | Â | Â | 7/ NCT04677088 10/ NCT02686372 10/ NCT02719782 | China | HBV antigen specific TCR T cells | HBsAg | Safety; pulmonary metastases of HCC decreased; valuable prophylaxis against HCC relapse provided | NCT04677088 NCT02686372 NCT02719782 | ||
CAR-T | Â | Â | 30 | China | GPC3-CAR-T cells | GPC3 | HCC cells were eradicared and tumor growth was efficiently suppressed in PDX model | NCT03198546 | [70] | |
 |  |  | 20 | China | HCC: CD133-CAR-T cells iCCA: Cocktail treatment comprised with VEGF-CAR-T, PD-1 monoclonal antibody and CD133-CAR-T | CD133 VEGF | Clinical outcomes of dvanced HCC patients improved with manageable safety profile by CD133-CAR-T; Advanced iCCA patient acquired 8.5-month and 4.5-month partial response from VEGF-CAR-T and CD133-CAR-T, respectively. | NCT02541370 |